L. Scopece

Medicine · Health Sciences

11h-index947citations25works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(21), Brain Metastases and Treatment(12), Cancer Treatment and Pharmacology(4), Neuroblastoma Research and Treatments(4), Nanoplatforms for cancer theranostics(3)

Publications25 total

Perioperative chemotherapy in gastric cancer: a monoinstitutional experience
Annals of Oncology·2016Open Access
Prognostic factors in newly diagnosed glioblastoma: Have we missed gender?
Journal of Clinical Oncology·2011· 3 cited
Efficacy of tailored treatment for high- and low-risk medulloblastoma in adults: A large prospective phase II trial.
Journal of Clinical Oncology·2010· 16 cited
Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma
Cancer·2009· 220 cited
Recurrence pattern after concomitant radio-chemotherapy in newly diagnosed glioblastoma patients: Correlation with <i>MGMT</i> promoter methylation status
Journal of Clinical Oncology·2008
2518 POSTER Prolonged maintenance chemotherapy with Temozolomide (TMZ) after concomitant treatment in newly diagnosed GBM: safety profile
European Journal of Cancer Supplements·2007· 1 cited
Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
British Journal of Cancer·2007· 210 citedOpen Access
Temozolomide (TMZ) 3 weeks on/1 week off in the treatment of progressive low grade gliomas: A phase II GICNO study
Journal of Clinical Oncology·2006· 4 cited
Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors
Journal of Neuro-Oncology·2006· 13 cited
Is protracted low-dose temozolomide feasible in glioma patients?
Neurology·2006· 37 cited
Primary and metastatic brain tumors.
PubMed·2006· 1 cited
Temozolomide-induced partial response in a patient with primary diffuse leptomeningeal gliomatosis
Journal of Neuro-Oncology·2005· 34 cited
Temozolomide (TMZ) for progressive primitive brain tumors: safety at 75 mg/m<sup>2</sup> a day for 21 days every 28: A GICNO (Italian Neuro-Oncology Group) study
Journal of Clinical Oncology·2005· 1 cited
Gefitinib (ZD1839) treatment for adult patients with progressive high-grade gliomas (HGG): An open label, single-arm, phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
Journal of Clinical Oncology·2005· 6 cited
A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro‐Oncologia
Cancer·2005· 85 cited
Temozolomide (TMZ) for 21/28 days in patients with progressive glioblastoma (GBM): Preliminary results of phase 2 study of GICNO (Italian Neuro-Oncology Group).
Neuro-Oncology·2005
Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma
British Journal of Cancer·2004· 57 citedOpen Access
Evaluation of 1p and 19q chromosomal alterations in oligodendroglial neoplasms using microdissection and microsatellite analysis technique and correlations with response to chemotherapy
Journal of Clinical Oncology·2004
Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors
Journal of Clinical Oncology·2004
Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors
Journal of Clinical Oncology·2004
page 1 of 2Next →

Frequent Co-authors

Enrico Franceschi(20), Giovanni Cavallo(11), Lucio Crinò(11), A. Tosoni(10), Alba A. Brandes(9), V. Blatt(7), Anna Paioli(7), R. Degli Esposti(7), Mario Ermani(6), F. Spagnolli(5), V. Mazzocchi(4), Andrea Pession(4), Giovanna Cavallo(4), Rosa Conforti(4), Emanuela Palmerini(4), Stefania Bartolini(4), S Rimondini(4), A.A. Brandes(4), M. Ermani(4), Alicia Tosoni(3)